Citation notice #9660 · 2026-08-11 06:34:47.387766+00:00

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

cites DOI: 10.1016/s1470-2045(14)70381-x, which carries a correction notice dated 2014-09-30. One-hop deterministic notice: the citation edge exists in the Pith bibliography graph; no model judged whether the citation was load-bearing.

This is not a judgment on the citing paper.

Citing paper Event page Original DOI Notice DOI File a formal challenge All reference changes

01Evidence

Raw extraction · citation context · bibliography index 1244

Ann Oncol 2010; 21: 1804-1809. 20100211. DOI: 10.1093/annonc/mdq020. 78. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244. 20140827. DOI: 10.1016/s1470-2045(14)70381-x. 79. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer 2021; 151: 20-24. 20201120. DOI: 10.1016/j.lungcan.2020.11.020. 80. Zhou C, Wu Y-L, Chen G, et al.

Parser render (TeX stripped for reading; raw above is the evidence)

Ann Oncol 2010; 21: 1804-1809. 20100211. DOI: 10.1093/annonc/mdq020. 78. Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): An open-label, randomised, multicentre, phase 2 study. Lancet Oncol 2014; 15: 1236-1244. 20140827. DOI: 10.1016/s1470-2045(14)70381-x. 79. Yamamoto N, Seto T, Nishio M, et al. Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study. Lung Cancer 2021; 151: 20-24. 20201120. DOI: 10.1016/j.lungcan.2020.11.020. 80. Zhou C, Wu Y-L, Chen G, et al

02Event

Type

Correction

Source

Crossref

Original DOI

10.1016/s1470-2045(14)70381-x

Notice DOI

10.1016/s1470-2045(14)70506-6

Date

2014-09-30

Title

Correction to Lancet Oncol 2014; 15: 1239

Reasons

['Erratum']

Work

DOI: 10.1016/s1470-2045(14)70381-x (?)

Schema constants (for re-runners): correction · crossref

03Dispute this notice

If this citation does not depend on the flagged claim, or the event is wrong, say so. Disputes are public. For a signed challenge against the paper itself, use the formal challenge form.